Norman Coleman, Gay Crawford to receive NCCS Stovall Award for advancing patient-centered care

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Norman Coleman, associate director of NCI’s Radiation Research Program and Gay Crawford, founding director of Cancer CAREpoint, were named recipients of the National Coalition for Cancer Survivorship’s Ellen L. Stovall Award for Innovation in Patient-Centered Cancer Care.

Named for longtime CEO of NCCS and three-time cancer survivor Ellen Stovall, who died in 2016, the award aims to honor her memory and advocacy by annually recognizing individuals, organizations, or other entities that are innovators in improving cancer care.

Coleman has been affiliated with NCCS since working with Stovall on the NCAB/Senate Subcommittee to Evaluate the National Cancer Program in 1993. He helped form the New England Coalition for Cancer Survivorship while at Harvard. He is senior scientific advisor to the International Cancer Expert Corps, a non-government organization focusing on global disparities in cancer care.

Crawford has counseled thousands of patients and families over the past 44 years. Some of the programs she helped found include: Hospice of the Valley, the second non-profit hospice in California; Courageous Kids, an American Cancer Society program for children with cancer; the California Cancer Registry; the Colon Cancer Free Zone, advocating for colon cancer screening; and was successful in lobbying the insurance industry to pay for breast reconstructions for patients.

In 2011, she was invited to serve as the first chair of Stanford’s new South Bay Cancer Center Patient and Family Advisory Council, helping to develop the program and keep the focus on patient-focused care. In 2013, Crawford founded Cancer CAREpoint, a Silicon Valley based nonprofit organization.

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login